Drug intelligence / Profile preview

C134

Development stage: Phase 1
Lead developer: Mustang Bio
Modality: Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intratumoral

Overview

C134 is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) designed for the treatment of malignant gliomas, including glioblastoma multiforme. It is modified to enhance its replication within tumor cells by incorporating the PKR evasion gene, IRS1, from human cytomegalovirus (HCMV), while maintaining safety in normal brain tissue by inducing early interferon (IFN) signaling. C134 works by directly infecting and lysing tumor cells and by eliciting a robust anti-tumor immune response.

Other names: genetically engineered herpes simplex virusoncolytic herpes simplex virus

Targets

EIF2AK2 (Interferon-induced protein kinase R)

Beyond the preview

Go deeper on C134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C134.

Explore the full profile